[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338522-105":59,"doc-detail-338522-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","selective-recruitment-of-antibodies-to-cancer-cells-and-immune-cell-mediated-killing-via-in-situ-click-chemistry","Selective Recruitment of Antibodies to Cancer Cells and Immune Cell-mediated Killing via In Situ Click Chemistry","","Many cancer immunotherapies rely on redirecting immune components to recognize tumor biomarkers, but the absence of universal, tumor-specific markers limits broad effectiveness. Solid tumors commonly feature extracellular acidity, enabling pH-low insertion peptide (pHLIP) accumulation and selective in vivo targeting. Here, pHLIP is used to drive tetrazine–trans-cyclooctene click ligation of human IgGs to cancer cell surfaces, yielding opsonized targets. The resulting engagement activates CD16a (FcγRIIIa)-mediated ADCC signaling and promotes NK-cell–driven killing of cancer targets.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/selective-recruitment-of-antibodies-to-cancer-cells-and-immune-cell-mediated-killing-via-in-situ-click-chemistry/338522/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/selective-recruitment-of-antibodies-to-cancer-cells-and-immune-cell-mediated-killing-via-in-situ-click-chemistry/338522.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are current biomarker-based cancer immunotherapies limited?","Question",{"text":112,"@type":113},"They depend on the availability of universal, tumor-specific biomarkers, but biomarker heterogeneity and tumor-associated expression restrict which patients and tumor types can be effectively treated.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does extracellular acidity play in this strategy?",{"text":117,"@type":113},"Solid tumors often develop an acidic extracellular microenvironment, which enables pHLIP to selectively accumulate in tumors due to its pH-dependent membrane insertion behavior.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the approach recruit antibodies and trigger immune killing?",{"text":121,"@type":113},"pHLIP is used to facilitate tetrazine–trans-cyclooctene click ligation of human IgGs onto cancer cell surfaces, forming opsonized targets. This induces ADCC signaling via CD16a (FcγRIIIa) on effector cells and promotes cancer cell killing by engineered NK cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338522,1790194821,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","ChemMedChem  \nResearch Article  \n[doi.org/10.1002/cmdc.202400356](doi.org/10.1002/cmdc.202400356)  \n[www.chemmedchem.org](www.chemmedchem.org)  \nSelective Recruitment of Antibodies to Cancer Cells and Immune Cell-mediated Killing via In Situ Click Chemistry  \nEmily Ankrom,[a] Brianna Dalesandro,[b] Marcos M. Pires,[b] and Damien Thévenin*[a]  \nMany current cancer immunotherapies function by redirecting immune system components to recognize cancer biomarkers and initiate a cytotoxic attack. The lack of a universal tumor biomarker limits the therapeutic potential of these approaches. However, one feature characteristic of nearly all solid tumors is extracellular acidity. This inherent acidity provides the basis for targeted drug delivery via the pH-low insertion peptide (pHLIP), which selectively accumulates in tumors in vivo due to a pHdependent membrane insertion propensity. Previously, we established that we could selectively decorate cancer cells with  \nantigen-pHLIP conjugates to facilitate antibody recruitment and subsequent killing by engineered effector cells via antibodydependent cellular cytotoxicity (ADCC) . Here, we present a novel strategy for opsonizing antibodies on target cell surfaces using click chemistry. We utilize pHLIP to facilitate selective tetrazine - trans-cyclooctene ligation of human IgGs to the cancer cell surface and induce ADCC. We demonstrate that our approach activates the primary ADCC signaling pathway via CD16a (FcγRIIIa) receptors on effector cells and induces the killing of cancer cell targets by engineered NK cells.  \nIntroduction  \nTumor tissues develop mechanisms to evade the immune response, such as downregulating human leukocyte antigen (HLA) class I proteins and inducing apoptosis of cytotoxic Tcells. [1–6] The field of onco-immunology aims to address the issue of immunologically “cold” cancers by redirecting immune system components to detect and destroy cancer cells. A subgroup of cancer immunotherapies includes monoclonal antibodies (mAbs), which tag surface biomarkers on cancerous cells and attract cytotoxic immune cells such as natural killer (NK) cells and macrophages. Cancer cell killing occurs via antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) . Existing monoclonal antibody therapies such as Rituximab and Obinutuzumab (antiCD20) are potent ADCC inducers and have shown good clinical efficacy against some B-cell malignancies. [7–12] Some emerging strategies that show promising antitumor activity involve synthetic bifunctional molecules that target tumors via overexpressed membrane proteins to display immunogenic epitopes extracellularly. [13–23] Their mechanism of action is ultimately to recruit circulating antibodies to the tumor cell surface and  \n[a] E. Ankrom, D. Thévenin  \nDepartment of Chemistry, Lehigh University, Bethlehem, Pennsylvania 18015, USA  \n610-758-2886  \n[E-mail: damien.thevenin@lehigh.edu](E-mail: damien.thevenin@lehigh.edu)[ ](E-mail: damien.thevenin@lehigh.edu)[b] B. Dalesandro, M. M. Pires  \nDepartment of Chemistry, University of Virginia, Charlottesville, Virginia 22904, USA  \n Supporting information for this article is available on the WWW under [https://doi.org/10.1002/cmdc.202400356](https://doi.org/10.1002/cmdc.202400356)  \n © 2024 The Authors. ChemMedChem published by Wiley-VCH GmbH. This isan open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.  \nsubsequent induction of ADCC or CDC. The efficacy of these therapies is quite limited due to the heterogeneity of biomarker expression, which renders only a subset of cancers with a specific phenotype treatable. Most cancer types lack reliable and robust expression of distinguishable surface markers, particularly solid tumors. [24] Furthermore, tumor b","cbCaikLc1G2Ksor8","https://ap.wps.com/l/cbCaikLc1G2Ksor8","pdf",1890245,11,"English","# Introduction\n## Limitations of biomarker-dependent immunotherapy\n## Tumor acidity as a targeting opportunity\n## pHLIP properties and prior targeting advances","[{\"question\":\"Why are current biomarker-based cancer immunotherapies limited?\",\"answer\":\"They depend on the availability of universal, tumor-specific biomarkers, but biomarker heterogeneity and tumor-associated expression restrict which patients and tumor types can be effectively treated.\"},{\"question\":\"What role does extracellular acidity play in this strategy?\",\"answer\":\"Solid tumors often develop an acidic extracellular microenvironment, which enables pHLIP to selectively accumulate in tumors due to its pH-dependent membrane insertion behavior.\"},{\"question\":\"How does the approach recruit antibodies and trigger immune killing?\",\"answer\":\"pHLIP is used to facilitate tetrazine–trans-cyclooctene click ligation of human IgGs onto cancer cell surfaces, forming opsonized targets. This induces ADCC signaling via CD16a (FcγRIIIa) on effector cells and promotes cancer cell killing by engineered NK cells.\"}]","Selective Recruitment of Antibodies to Cancer Cells and Immune Cell-mediated Killing via In Situ Click Chemistry | PDF",1790024029,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/498b4163ad37f619f5e0ec6ffc0b9644.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0dc8ee941ee854b08851793405a777f5.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db500fe1a8e0f3f88a6fdf8989c69213.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43c05e04337655beafadecc7e51d2010.webp",980,1385]